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Background
We recently demonstrated that intradermal (ID) injection
with electropororation (EP) of a new HIV DNA vaccine
induced strong and persistent specific T-cells in macaques.
Here, we used an equivalent vaccine encoding SIVmac251
antigens in order to study its efficacy in SIV mucosal chal-
lenge of macaques.
Methods
Eighteen macaques were vaccinated with 1 mg of the
auxo-GTU-MultiSIV DNA at week 0, 4 and 12: either by
the ID route only (n = 6), or by the ID route combined
with EP (ID+EP; n = 6) or ID+EP with co-injection of a
plasmid used as ''genetic-adjuvant'' (n = 6). A control
group of unvaccinated animal was included (n = 6).
Results
Before challenge, all animals raised SIV-specific T-cells as
evidenced by IFN-γ ELISPOT (110 ± 42, 921 ± 310 and
905 ± 252 spots/106 cells in the ID only, ID+EP and
ID+EP+genetic-adjuvant groups, respectively). Weak and
transient antibody responses were detected. All animals
were intrarectally challenged with pathogenic SIVmac251.
T-cell responses increased in both ID+EP groups as early
as week 1 post-challenge (3,898 ± 395 and 3,031 ± 893
spots, respectively), and up to 12,000 spots by week 2.
Macaques immunized ID only raised delayed and lower
responses remaining earlier and higher than in controls.
At peak of viremia, plasma viral load was significantly
reduced (p = 0.0104) in the ID+EP group. Interestingly,
no reduction of plasma viral load was observed by that
time in the genetic-adjuvant group despite high anamnes-
tic responses. Differences in anti-Gag responses may
explain this observation. Viremia was not reduced in the
ID only group. At set-point, although similar plasma viral
load in all groups, reduction of SIV-DNA copies in rectal
biopsies was observed in the vaccinated animals.
Conclusion
Electroporation results induced high anamnestic T-cells
responses which are better associated with the control of
early plasma viremia. Impact of vaccine on disease pro-
gression is currently under evaluation.
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